Detalles de la búsqueda
1.
Crosstalk between oxygen signaling and iron metabolism in renal interstitial fibroblasts.
J Clin Biochem Nutr;
74(3): 179-184, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38799135
2.
Usefulness of gallium-67 scintigraphy for evaluating the histopathological activity in interstitial nephritis.
Clin Exp Nephrol;
27(3): 251-261, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36574102
3.
Activation of α7 nicotinic acetylcholine receptors attenuates monocyte-endothelial adhesion through FUT7 inhibition.
Biochem Biophys Res Commun;
590: 89-96, 2022 01 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34973535
4.
What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances.
Int J Mol Sci;
24(1)2022 Dec 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36614011
5.
A novel method for successful induction of interdigitating process formation in conditionally immortalized podocytes from mice, rats, and humans.
Biochem Biophys Res Commun;
570: 47-52, 2021 09 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34271436
6.
Update on diagnosis, pathophysiology, and management of diabetic kidney disease.
Nephrology (Carlton);
26(6): 491-500, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33550672
7.
Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
J Am Soc Nephrol;
31(3): 560-577, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31996409
8.
[Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Rinsho Ketsueki;
62(5): 371-377, 2021.
Artículo
en Japonés
| MEDLINE | ID: mdl-34108317
9.
JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
Am J Physiol Renal Physiol;
318(1): F14-F24, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31630548
10.
Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
Am J Physiol Renal Physiol;
318(2): F388-F401, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31841388
11.
Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage.
Kidney Int;
97(4): 687-701, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32033782
12.
The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
Kidney Int;
97(5): 934-950, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32171449
13.
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Curr Opin Nephrol Hypertens;
29(4): 414-422, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32452915
14.
Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases.
Curr Opin Nephrol Hypertens;
29(1): 128-135, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31592832
15.
Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet.
Lab Invest;
99(8): 1217-1232, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30952940
16.
Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury.
Kidney Int;
96(1): 129-138, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30979565
17.
ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis.
Kidney Int;
95(3): 577-589, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30639234
18.
Regional variance in patterns of prescriptions for chronic kidney disease in Japan.
Clin Exp Nephrol;
23(6): 859-864, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30820707
19.
Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.
Clin Exp Nephrol;
23(2): 231-243, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30182223
20.
Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.
Clin Exp Nephrol;
23(3): 435, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30673934